Biologic therapy during pregnancy was not associated with adverse outcomes for most patients in a retrospective study presented at AAAAI 2026.

Chinese pharmaceutical firms are poised for profit growth, driven by innovative drug sales and licensing deals, despite pricing pressures.

The data suggest significant challenges in maintaining long-term disease control with advanced systemic therapies for atopic dermatitis.

Artificial intelligence research biotech Earendil Labs has penned an $885 million deal to use WuXi XDC’s linker-payload technology to create next-gen antibody-drug conjugates. | AI research biotech ...

AbCellera Biologics Inc. (NASDAQ: ABCL) is one of the most promising penny stocks under $5 to buy. On February 24, AbCellera Biologics announced its Q4 and full-year 2025 financial results, marking a ...

Fingerpaint Group, a 2025 MM+M Agency 100 honoree, announced three promotions: Bill McEllen will elevate from global president to CEO, succeeding founder Ed Mitzen; Mark Willmann from president of ...

There are many interesting companies that make Bedford their home. Below is a quick recap of what’s happening around town in ...

The drugmaking unit of South Korea’s Lotte Group is betting on growth from a global shift in pharmaceutical production away from Chinese players amid rising geopolitical tension and tariff ...

Brad Tade, CFO & Treasurer, stated, "Our full year 2025 financial results demonstrate ADMA's consistent execution, expanding profitability and earnings power." Tade reported fourth quarter revenue of ...

Q4 2025 Earnings Call February 25, 2026 4:30 PM ESTCompany ParticipantsAdam Grossman - Co-Founder, President, CEO ...

While many Baby Boomers have enjoyed a long bull market over the past 35 years, there is a point when income becomes more critical than stock appreciation. The reason is simple: those who leave their ...